Adial Pharmaceuticals Announces Third-Party Sales and Distribution Agreement with Brik for Rapid Result COVID-19 Antibody Test Kits Aug 6, 2020
Adial Pharmaceuticals Receives European Medicines Agency (EMA) Agreement on the Pediatric Investigation Plan (PIP) for AD04 in Alcohol Use Disorder Jul 22, 2020
Adial Pharmaceuticals Announces Approval to Commence Landmark ONWARD(TM) Pivotal Phase 3 Trial in Sweden and Estonia Jul 6, 2020
Adial Pharmaceuticals Announces Commencement of Landmark ONWARD(TM) Pivotal Phase 3 Trial in Poland Jun 25, 2020
Adial Pharmaceuticals Announces Commencement of the Landmark ONWARD(TM) Pivotal Phase 3 Clinical Trial in Latvia Jun 17, 2020
Adial Pharmaceuticals Closes Previously Announced $5.2 Million Registered Direct Offering Jun 15, 2020
Adial Pharmaceuticals Announces Approval to Commence Landmark ONWARD™ Pivotal Phase 3 Trial in Poland Jun 11, 2020
Adial Pharmaceuticals Announces Pricing of $5.2 Million Registered Direct Offering Priced At-The-Market Jun 9, 2020
